Jetske van der Schaar is not even 40 years old and already knows for sure that in about 15 years she will develop Alzheimer's disease. She has the Alzheimer's gene that leads to early dementia. And there is nothing to be done about that. Not yet. Because the good news is that the Brain Research Center is participating in an international study by Washington University in St. Louis (VSt) that should lead to a new drug. A drug that should prevent people like Jetske, who are genetically predisposed, from developing dementia at an early age.
This week Jetske visited us. That same evening she was a guest on Op1, together with neurologist Philip Scheltens, director of the Alzheimer Centre Amsterdam and scientific advisor at the Brain Research Center. Her fight is our fight. That is why starting this research, called DIAN-TU, means so much to me personally. It is exactly the kind of research for which we founded the Brain Research Center: leading international research into solutions for difficult-to-treat brain diseases, which we carry out together with our participants, like Jetske.
People like her have a 100% chance of developing the disease and a 50% chance of passing the gene on to their children. Jetske wrote a book about life with this hereditary disorder: Eeuwige lente (Eternal Spring).
The DIAN-TU study is a particularly important study for several reasons. First, because there is currently no treatment that can prevent or slow the progression of Alzheimer’s disease. Second, because the rare hereditary form leads to a “pure” Alzheimer’s disease process in people who are otherwise healthy, which is of great scientific value. Finally, because it is being conducted with an extremely motivated group of people who want to contribute to a solution or, what would be the most beautiful thing, who could themselves benefit from the experimental treatment.
Not everyone was immediately convinced of the great importance of this research. The medical ethics review committee initially rejected the DIAN-TU study. They found the study too taxing for the participants. This caused disbelief and frustration for Jetske and her fellow sufferers who also carry a hereditary Alzheimer’s mutation and are looking for a solution. After we appealed to the Central Commission for Human Research (CCMO) in The Hague, the study was fortunately still approved and we started.
We don’t know if a medicine will be available for Jetske in time, but the knowledge that she can contribute to the solution makes a world of difference for her. Because there are many more people like Jetske. And for future generations, the medicine, hopefully, will be available in time.
Would you like to order the book by Jetske van der Schaar?